Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Channeling Hope Trial 1
NCT07845825Phase 1Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Oct 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aprepitant in congenital contractures of the limbs and face, hypotonia, and developmental delay (CLIFAHDD), sponsored by UT Health San Antonio. Primary endpoints: Number of Adverse Events at 24 weeks, Dose-Limiting Toxicity at 24 weeks and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
aprepitant
03
Conditions
congenital contractures of the limbs and face, hypotonia, and developmental delay (CLIFAHDD)
Beyond the preview
Go deeper on NCT07845825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845825.